

**Name of the Issue: Eris Lifesciences Limited**

**1 Type of Issue** IPO

**2 Issue Size (Rs. Cr)** 1,741.16

*Source: Prospectus dated June 21, 2017*

**3 Grade of issue along with name of the rating agency**

**Name** Not applicable

**Grade** Not applicable

**4 Subscription Level (Number of times)** 3.29

*Notes:*

<sup>1)</sup> *The above figures are before technical rejections*

*Source: Final Post Issue Report*

**5 QIB Holding (as a %age of Outstanding Capital) as disclosed to Stock Exchanges**

Particulars	Number of Shares	%age
(i) On Allotment <sup>(1)</sup>		17.41%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (June 30, 2017)		17.39%
(iii) at the end of 1st FY (March 31, 2018)		19.41%
(iv) at the end of 2nd FY (March 31, 2019)		19.79%
(v) at the end of 3rd FY (March 31, 2020)		21.37%

*Source:*

<sup>(1)</sup> *Basis of Allotment*

## 6 Financials of the issuer

(Rs. Crore)

Parameters	1st FY (FY 2018) <sup>(1)</sup>	2nd FY (FY 2019)	3rd FY (FY 2020)
Net Sales/ Income from operations	855.6	982.2	1074.1
Net Profit	295.0	290.8	295.3
Paid up Equity Share Capital	13.8	13.8	13.6
Reserves excluding revaluation reserves	847.6	1136.8	1282.8

<sup>(1)</sup> Consolidated Financial Results as disclosed to BSE and NSE

## 7 Trading Status

Particulars	BSE	NSE
(i) at the end of 1st FY (FY 2018)	Infrequently Traded	Frequently Traded
(ii) at the end of 2nd FY (FY 2019)	Infrequently Traded	Infrequently Traded
(iii) at the end of 3rd FY (FY 2020)	Infrequently Traded	Frequently Traded

## 8 Change in Directors

Particulars	Name of Director	Appointed / Resigned
During year ended March 31, 2018	Prashant Gupta	Appointed in April 2018
During year ended March 31, 2019	Himanshu Shah	Resigned
During year ended March 31, 2020 <sup>(1)</sup>	Mr. Cherian Mathew	Appointed

<sup>(1)</sup> Change in Directors not disclosed as the reporting for the fiscal year has not been completed/ disclosed

## 9 Status of implementation of project/ commencement of commercial production

(i) Details of Estimated Schedule of Implementation of Projects forming part of Objects of the Issue	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

All the above information is updated till February 28, 2021 unless stated otherwise.

**10 Status of utilization of issue proceeds**

(i) As disclosed in the offer document	Not Applicable
(ii) Actual utilization	Not Applicable
(iii) Reasons for deviation, if any	Not Applicable

**11 Comments of monitoring agency, if applicable** Not applicable

- (a) Comments on use of funds  
 (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document  
 (c) Any other reservations expressed by the monitoring agency about the end use of funds

**12 Pricing Data**

Issue Price (Rs.) Rs. 603

Price parameters	At close of listing day i.e. June 29, 2017	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day ( <sup>1</sup> )	As at the end of FY 2018 ( <sup>1</sup> )			As at the end of FY 2019 ( <sup>1</sup> )			As at the end of FY 2020		
				Closing price	High	Low	Closing price	High	Low	Closing price	High	Low
Market Price (NSE)	601.50	608.25	568.70	799.75	803.00	760.00	644.90	648.80	633.50	368.90	392.35	365.00
NSE Nifty	9,504.10	10,014.50	9,871.50	10,113.70	10,158.35	10,096.90	11,623.90	11,630.35	11,570.15	8,597.75	8,678.30	8,358.00
Sectoral Index	9428.2	9,672.60	9,297.90	8,358.05	8,456.70	8,332.15	9,346.55	9,366.65	9,240.80	7,176.50	7,224.35	6,951.40

*NIFTY Pharma is the sectoral index for above disclosure*
*(<sup>1</sup>) In case March 31 is a holiday then previous working day has been considered*
*All the above information is updated till February 28, 2021 unless stated otherwise.*

**13 Basis for Issue Price**

Accounting ratio	Name of Company	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (FY 2018)	At the end of 2nd FY (FY 2019)	At the end of 3rd FY (FY 2020)
EPS (Basic)(Rs.)	<b>Issuer :</b>	17.61	21.39 ~	21.13 ~	21.61 ~
	<b>Peer Group:</b>				
	GlaxoSmithKline Pharmaceuticals Limited	39.80	41.41 ~	26.29 ~	5.5 ~
	Abbott India Limited	130.19	188.81 ~	211.93 ~	279.04 ~
	Sanofi India Limited	129.13		165.3 ~	179.85 ~
	Pfizer Limited	73.61	78.8 ~	93.8 ~	111.28 ~
	<b>Industry Avg:</b>	93.18	103.01	124.33 ~	119.456 ~
P/E (Basic EPS)	<b>Issuer:</b>	34.24	31.12 ~	30.45 ~	17.05 ~
	<b>Peer Group:</b>				
	GlaxoSmithKline Pharmaceuticals Limited	61.51	67.02 ~	42.72 ~	226.41 ~
	Abbott India Limited	31.41	39.13 ~	34.43 ~	55.39 ~
	Sanofi India Limited	31.65	33.49 ~	38.44 ~	39.01 ~
	Pfizer Limited	23.48	32.97 ~	35.41 ~	36.17 ~
	<b>Industry Avg:</b>	37.01	43.15	37.75 ~	89.26 ~
RoNW (%)	<b>Issuer:</b>	44.84	33.29 ~	28.91 ~	22.78 ~
	<b>Peer Group:</b>				
	GlaxoSmithKline Pharmaceuticals Limited	16.78	17.05 ~	21.22 ~	4.9 ~
	Abbott India Limited	19.95	23.7 ~	24.33 ~	24.18 ~
	Sanofi India Limited	17.11	16.68 ~	17.93 ~	16.28 ~
	Pfizer Limited	13.92	13.42 ~	15.07 ~	14.73 ~
	<b>Industry Avg:</b>	16.94	17.71	19.64 ~	17.71 ~
NAV per share	<b>Issuer:</b>	39.21	64.43 ~	83.66 ~	95.47 ~
	<b>Peer Group:</b>				
	GlaxoSmithKline Pharmaceuticals Limited	236.93	242.89 ~	126.47 ~	107.47 ~
	Abbott India Limited	652.70	796.6 ~	945.22 ~	1144.37 ~
	Sanofi India Limited	753.62	879.9 ~	963.6 ~	1060.46 ~
	Pfizer Limited	528.74	586.52 ~	658.25 ~	742.22 ~
	<b>Industry Avg:</b>	543.00	626.48	855.69 ~	763.63 ~

Notes:

<sup>(1)</sup> Sourced from the Prospectus dated June 21, 2017

**14 Any other material information**
**Particulars**

For updates and further information on material information please visit stock exchanges website [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)

All the above information is updated till February 28, 2021 unless stated otherwise.